Bacteriophages and their enzymes in biofilm control

Current Pharmaceutical Design

Volumn 21, Issue 1, 2015, Pages 85-99

  Chan, Benjamin K ^a,b   Abedon, Stephen T ^c  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

Antibacterial agents; Biocontrol; Biofilm; Biofilm control; Endolysin; EPS depolymerase; Exracellular polysaccharide depolymerase; Extracellular polymeric substance depolymerase; Lysin; Phage therapy; Phage mediated biocontrol

Indexed keywords

ENDOLYSINE; EXTRACELLULAR POLYMERIC SUBSTANCE; LYSINE; POLYGALACTURONASE; POLYMER; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT;

ACINETOBACTER BAUMANNII; ACINETOBACTER JOHNSONII; AGGREGATIBACTER ACTINOMYCETEMCOMITANS; ARTICLE; BACILLUS SUBTILIS; BACTERIOPHAGE; BIOFILM; CAMPYLOBACTER JEJUNI; ESCHERICHIA COLI; KLEBSIELLA PNEUMONIAE; LISTERIA MONOCYTOGENES; NONHUMAN; PANTOEA AGGLOMERANS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS FLUORESCENS; PSEUDOMONAS PUTIDA; SPHAEROTILUS; SPHAEROTILUS NATANS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STAPHYLOCOCCUS LENTUS; ANIMAL; BACTERIUM; ENZYMOLOGY; HUMAN; ISOLATION AND PURIFICATION; MICROBIOLOGY; PLANKTON; VIROLOGY;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIOPHAGES; BIOFILMS; HUMANS; PLANKTON;

EID: 84919718946     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612820666140905112311     Document Type: Article

References (189)

1. Hall MR, McGillicuddy E, Kaplan LJ. Biofilm: basic principles, pathophysiology, and implications for clinicians Surg Infect (Larchmt) 2014 15: 1-7.
2. Flemming HC, Wingender J. The biofilm matrix Nat Rev Microbiol 2010 8: 623-33.
3. Krisch HM. The view from Les Treilles on the origins, evolution and diversity of viruses Res Microbiol 2003; 154: 227-9.
4. Brüssow H, Canchaya C, Hardt WD. Phages and the evolution of bacterial pathogens: from genomic rearrangements to lysogenic conversion Microbiol Mol Biol Rev 2004 68: 560-602, table.
5. Pal C, Macia MD, Oliver A, Schachar I, Buckling A. Coevolution with viruses drives the evolution of bacterial mutation rates Nature 2007 450: 1079-81.
6. Galán JC. Phage-shaping evolution of bacterial pathogenicity and resistance In: Nombela, C., Cassell GH, Gutierrez-fuentes JA. Evolutionary Biology of Bacterial and Fungal Pathogens. Washington, D. C., ASM Press 2008; 167-84.
7. Casas V, Maloy S. Role of bacteriophage-encoded exotoxins in the evolution of bacterial pathogens Future Microbiol 2011; 6: 1461-73.
8. Weinbauer MG, Agis M, Bonilla-Findji O, Malits A, Winter C. Bacteriophage in the environment In: Mc Grath, S. and van Sinderen, D., Bacteriophage: Genetics and Molecular Biology. Norfolk, UK, Caister Academic Press 2007; 61-92.
9. Danovaro R, Corinaldesi C, Dell'Anno A, et al. Marine viruses and global climate change FEMS Microbiol Rev 2011; 35: 993-1034.
10. Suttle CA. Marine viruses-major players in the global ecosystem Nat Rev Microbiol 2007 5: 801-12.
11. Breitbart, M. Marine viruses: truth or dare Ann Rev Mar Sci 2012; 4: 425-48.
12. Hyman P, Abedon ST. Bacteriophages in Health and Disease Wallingford, UK, CABI Press. 2012.
13. Abedon ST. Bacteriophage Ecology: Population Growth, Evolution, and Impact of Bacterial Viruses Cambridge UK, Cambridge University Press. 2008.
14. Abedon ST. Bacteriophages and Biofilms: Ecology, Phage Therapy, Plaques Hauppauge, New York, Nova Science Publishers. 2011.
15. Vu B, Chen M, Crawford RJ, Ivanova EP. Bacterial extracellular polysaccharides involved in biofilm formation Molecules 2009; 14: 2535-54.
16. Lei Y, Oshima T, Ogasawara N, Ishikawa S. Functional analysis of the protein Veg, which stimulates biofilm formation in Bacillus subtilis. J Bacteriol 2013 195: 1697-705.
17. Sutherland I. Biofilm exopolysaccharides: a strong and sticky framework. Microbiology 2001 147: 3-9.
18. Cai W, De La Fuente L, Arias CR. Biofilm formation by the fish pathogen Flavobacterium columnare: development and parameters affecting surface attachment. Appl Environ Microbiol 2013.
19. Worthington RJ, Richards JJ, Melander C. Small molecule control of bacterial biofilms Org Biomol Chem 2012; 10: 7457-74.
20. Mosig G, Eiserling F. T4 and related phages: structure and development In: Calendar, R. and Abedon, S. T., The Bacteriophages. Oxford, Oxford University Press. 2006.
21. Sutherland IW, Hughes KA, Skillman LC, Tait K. The interaction of phage and biofilms FEMS Microbiol Lett 2004; 232: 1-6.
22. Scholl D, Merril C. Polysaccharide-degrading phages In: Waldor M. K., Friedman D. I., and Adhya S. L., Phages: Their Role in Bacterial Pathogenesis and Biotechnology. Washington DC, ASM Press 2005; 400-14.
23. Drulis-Kawa Z, Majkowska-Skrobek G, Maciejewska B, Delattre AS, Lavigne R. Learning from bacteriophages-advantages and limitations of phage and phage-encoded protein applications. Curr Protein Pept Sci 2012; 13: 699-722.
24. Shen Y, Mitchell MS, Donovan DM, Nelson DC. Phage-based enzybiotics In: Hyman, P. and Abedon, S. T., Bacteriophages in Health and Disease. Wallingford, UK, CABI Press 2012; 217-39.
25. Yan J, Mao J, Xie J. Bacteriophage Polysaccharide depolymerases and biomedical applications. BioDrugs 2014; 28, 265-74.
26. Tait K, Skilman LC, Sutherland IW. The efficacy of bacteriophage as a method of biofilm eradication. Biofouling 2002; 18: 305-11.
27. Azeredo J, Sutherland IW. The use of phages for the removal of infectious biofilms. Curr Pharm Biotechnol 2008; 9: 261-6.
28. Donlan RM. Preventing biofilms of clinically relevant organisms using bacteriophage Trends Microbiol 2009 17: 66-72.
29. Abedon ST. Bacteriophages and biofilms In: Bailey, W. C., Biofilms: Formation, Development and Properties. Hauppauge, New York, Nova Science Publishers 2010; 1-58.
30. Brussow H. Bacteriophage-host interaction: from splendid isolation into a messy reality Curr Opin Microbiol 2013 16: 500-6.
31. Young R. Bacteriophage lysis: mechanisms and regulation. Microbiol Rev 1992; 56: 430-81.
32. Abedon ST. Lysis from without Bacteriophage 2011; 1: 46-9.
33. Fischetti VA. Bacteriophage lytic enzymes: novel anti-infectives. Trends Microbiol 2005; 13: 491-6.
34. Fischetti VA. The use of phage lytic enzymes to control bacterial infections In: Kutter, E. and Sulakvelidze A., Bacteriophages: Biology and Application. Boca Raton, Florida, CRC Press 2005; 321-34.
35. Fischetti VA. Bacteriophage lysins as effective antibacterials. Curr Opin Mirobiol 2008; 11: 393-400.
36. Fischetti VA, Nelson D, Schuch R. Reinventing phage therapy: are the parts greater than the sum? Nat Biotech 2006; 24: 1508-11.
37. Starck CJ, Bonocora RP, Hoopes JT, Nelson DC. Bacteriophage lytic enzymes as antimicrobials In: Sabour P. M. and Griffiths M. W. Bacteriophages in the Control of Food-and Waterborne Pathogens. Washington, DC, ASM Press 2010; 137-56.
38. Nelson DC, Schmelcher M, Rodriguez-Rubio L, Klumpp J, Pritchard DG, Dong S, Donovan DM. Endolysins as antimicrobials. Adv Virus Res 2012; 83: 299-365.
39. Pastagia M, Schuch R, Fischetti VA, Huang DB. Lysins: The arrival of pathogen-directed anti-infectives. J Med Microbiol 2013; 62: 1506-16.
40. Rodríguez-Rubio L, Martinez B, Donovan DM, Rodriguez A, Garcia P. Bacteriophage virion-associated peptidoglycan hydrolases: potential new enzybiotics. Crit Rev Microbiol 2013; 39: 427-34.
41. Derlon N, Koch N, Eugster B, et al. Activity of metazoa governs biofilm structure formation and enhances permeate flux during Gravity-Driven Membrane (GDM) filtration. Water Res 2013 47: 2085-95.
42. Lawrence JR, Scharf B, Packroff G, Neu TR. Microscale evaluation of the effects of grazing by invertebrates with contrasting feeding modes on river biofilm architecture and composition. Microb Ecol 2002; 44: 199-207.
43. Dashiff A, Kadouri DE. Predation of oral pathogens by Bdellovibrio bacteriovorus 109. J Mol Oral Microbiol 2011; 26: 19-34.
44. Dashiff A, Junka RA, Libera M, Kadouri DE. Predation of human pathogens by the predatory bacteria Micavibrio aeruginosavorus and Bdellovibrio bacteriovorus. J Appl Microbiol 2011; 110: 431-44.
45. Dwidar M, Hong S, Cha M, Jang J, Mitchell RJ. Combined application of bacterial predation and carbon dioxide aerosols to effectively remove biofilms Biofouling 2012; 28: 671-80.
46. Derlon N, Peter-Varbanets M, Scheidegger A, Pronk W, Morgenroth E. Predation influences the structure of biofilm developed on ultrafiltration membranes Water Res 2012; 46: 3323-33.
47. Erken M, Farrenschon N, Speckmann S, Arndt H, Weitere M. Quantification of individual flagellate-bacteria interactions within semi-natural biofilms Protist 2012; 163: 632-42.
48. Weitere M, Bergfeld T, Rice SA, Matz C, Kjelleberg S. Grazing resistance of Pseudomonas aeruginosa biofilms depends on type of protective mechanism, developmental stage and protozoan feeding mode Environ Microbiol 2005; 7: 1593-601.
49. Erken M, Weitere M, Kjelleberg S, McDougald D. In situ grazing resistance of Vibrio cholerae in the marine environment FEMS Microbiol Ecol 2011; 76: 504-12.
50. Koh KS, Matz C, Tan CH, et al. Minimal increase in genetic diversity enhances predation resistance Mol Ecol 2012; 21: 1741-53.
51. Chavez-Dozal A, Gorman C, Erken M, Steinberg PD, McDougald D, Nishiguchi MK. Predation response of Vibrio fischeri biofilms to bacterivorus protists Appl Environ Microbiol 2013; 79: 553-8.
52. Sun S, Kjelleberg S, McDougald D. Relative contributions of Vibrio polysaccharide and quorum sensing to the resistance of Vibrio cholerae to predation by heterotrophic protists PLoS One 2013; 8: e56338.
53. Anderson IJ, Watkins RF, Samuelson J, et al. Gene discovery in the Acanthamoeba castellanii genome Protist 2005; 156: 203-14.
54. Kutter E, Sulakvelidze A. Bacteriophages: Biology and Application Boca Raton, FL, CRC Press. 2005.
55. Waldor MK, Friedman D, Adhya S. Phages: Their Role in Bacterial Pathogenesis and Biotechnology Washington, DC, ASM Press. 2005.
56. Calendar R, Abedon ST. The Bacteriophages Oxford, Oxford University Press. 2006.
57. Mc Grath S, van Sinderen D. Bacteriophage: Genetics and Molecular Biology Norfolk, UK, Caister Academic Press. 2007.
58. Ackermann HW, Prangishvili D. Prokaryote viruses studied by electron microscopy Arch Virol 2012; 157: 1843-9.
59. Hyman P, Abedon ST. Smaller fleas: viruses of microorganisms Scientifica 2012; 2012: 734023.
60. Scanlan PD, Buckling A. Co-evolution with lytic phage selects for the mucoid phenotype of Pseudomonas fluorescens SBW25 ISME J 2012; 6: 1148-58.
61. Abedon ST. Thinking about microcolonies as phage targets Bacteriophage 2012; 2: 200-4.
62. Hyman P, Abedon ST. Bacteriophage host range and bacterial resistance Adv Appl Microbiol 2010; 70: 217-48.
63. Labrie SJ, Samson JE, Moineau S. Bacteriophage resistance mechanisms Nat Rev Microbiol 2010; 8: 317-27.
64. Abedon ST. Spatial vulnerability: bacterial arrangements, microbiolonies, and biofilms as responses to low rather than high phage densities Viruses 2012; 4: 663-87.
65. Stewart FM, Levin BR. The population biology of bacterial viruses: Why be temperate Theor Pop Biol 1984; 26: 93-117.
66. Winter C, Bouvier T, Weinbauer MG, Thingstad TF. Trade-offs between competition and defense specialists among unicellular planktonic organisms: the "killing the winner" hypothesis revisited Microbiol Mol Biol Rev 2010; 74: 42-57.
67. Kay MK, Erwin TC, McLean RJ, Aron GM. Bacteriophage ecology in Escherichia coli and Pseudomonas aeruginosa mixed biofilm communities Appl Environ Microbiol 2011; 77: 821-9.
68. Harper DR. Biological control by microorganisms, The Encyclopedia of Life Sciences. Chichester, West Sussex, England, UK, John Wiley & Sons 2006; 1-10.
69. Abedon ST. Kinetics of phage-mediated biocontrol of bacteria Foodborne Pathog Dis 2009; 6: 807-15.
70. Abedon ST. The 'nuts and bolts' of phage therapy Curr Pharm Biotechnol 2010; 11: 1.
71. Sabour PM, Griffiths MW. Bacteriophages in the Control of Food and, Waterborne Pathogens Washington, DC, ASM Press. 2010.
72. Borysowski J, Miedzybrodzki R, Górski A. Phage Therapy: Current Research and Applications Norfolk, UK, Caister Academic Press. 2014.
73. Sillankorva S, Azeredo J. The use of bacteriophages and bacteriophage-derived enzymes for clinically relevant biofilm control In: Borysowski, J., Miedzybrodzki, R., and Górski, A., Phage Therapy: Current Research and Applications. Norfolk, UK, Caister Academic Press. 2014; 309-329.
74. Payne RJH, Jansen VAA. Understanding bacteriophage therapy as a density-dependent kinetic process J Theor Biol 2001; 208: 37-48.
75. Payne RJH, Phil D, Jansen VAA. Phage therapy: The peculiar kinetics of self-replicating pharmaceuticals Clin Pharmacol Ther 2000; 68: 225-30.
76. Payne RJH, Jansen VAA. Pharmacokinetic principles of bacteriophage therapy Clin Pharmacokinet 2003; 42: 315-25.
77. Levin BR, Bull JJ. Population and evolutionary dynamics of phage therapy Nat Rev Microbiol 2004; 2: 166-73.
78. Bull JJ, Regoes RR. Pharmacodynamics of non-replicating viruses, bacteriocins and lysins Proc R Soc Lond B Biol Sci 2006; 273: 2703-12.
79. Górski A, Wazna E, Dabrowska B-W, Switala-Jelén K, Miedzybrodzki R. Bacteriophage translocation FEMS Immunol Med Microbiol 2006; 46: 313-9.
80. Abedon ST, Thomas-Abedon C. Phage therapy pharmacology Curr Pharm Biotechnol 2010; 11: 28-47.
81. Abedon S. Phage therapy pharmacology: calculating phage dosing Adv Appl Microbiol 2011 77: 1-40.
82. Curtright AJ, Abedon ST. Phage therapy: emergent property pharmacology J Bioanal Biomed 2011 S3: 010.
83. Jonczyk E, Klak M, Miedzybrodzki R, Górski A. The influence of external factors on bacteriophages-review Folia Microbiol (Praha) 2011; 56: 191-200.
84. Ryan EM, Gorman SP, Donnelly RF, Gilmore BF. Recent advances in bacteriophage therapy: how delivery routes, formulation, concentration and timing influence the success of phage therapy J Pharmacy Pharamcol 2011; 63: 1253-64.
85. Abedon ST. Phage therapy best practices In: Hyman, P. and Abedon, S. T., Bacteriophages in Health and Disease. Wallingford, UK, CABI Press. 2012; 256-72.
86. Chan BK, Abedon ST. Phage therapy pharmacology: phage cocktails Adv Appl Microbiol 2012; 78: 1-23.
87. Olszowska-Zaremba N, Borysowski J, Dabrowska J, Górski A. Phage translocation, safety, and immunomodulation In: Hyman, P. and Abedon, S. T., Bacteriophages in Health and Disease. Wallingford, UK, CABI Press. 2012; 168-84.
88. Ryan E, Garland MJ, Singh TR, et al. Microneedle-mediated transdermal bacteriophage delivery Eur J Pharm Sci 2012; 47: 297-304.
89. Abedon ST. Bacteriophages as drugs: the pharmacology of phage therapy. In: Borysowski, J., Miedzybrodzki, R., and Górski, A., Phage Therapy: Current Research and Applications. Norfolk, UK, Caister Academic Press. 2014; 69-100.
90. Abedon ST. Phage therapy: eco-physiological pharmacology Scientifica 2014; 581639.
91. Chhibber S, Nag D, Bansal S. Inhibiting biofilm formation by Klebsiella pneumoniae B5055 using an iron antagonizing molecule and a bacteriophage BMC Microbiol 2013; 13: 174.
92. Ganegama Arachchi GJ, Cridge AG, et al. Effectiveness of phages in the decontamination of Listeria monocytogenes adhered to clean stainless steel, stainless steel coated with fish protein, and as a biofilm J Ind Microbiol Biotechnol 2013; 40: 1105-16.
93. Lungren MP, Christensen D, Kankotia R, Falk I, Paxton BE, Kim CY. Bacteriophage K for reduction of biofilm on central venous catheter material Bacteriophage 2013; 3: e26825.
94. Phee A, Bondy-Denomy J, Kishen A, Basrani B, Azarpazhooh A, Maxwell K. Efficacy of bacteriophage treatment on Pseudomonas aeruginosa biofilms J Endod 2013; 39: 364-9.
95. Seth AK, Geringer MR, Nguyen KT, et al. Bacteriophage therapy for Staphylococcus aureus biofilm-infected wounds: a new approach to chronic wound care Plast Reconstr Surg 2013; 131: 225-34.
96. Yilmaz C, Colak M, Yilmaz BC, Ersoz G, Kutateladze M, Gozlugol M. Bacteriophage therapy in implant-related infections: an experimental study J Bone Joint Surg Am 2013; 95: 117-25.
97. Zhang Y, Hunt HK, Hu Z. Application of bacteriophages to selectively remove Pseudomonas aeruginosa in water and wastewater filtration systems Water Res 2013; 47: 4507-18.
98. Zhang Y, Hu Z. Combined treatment of Pseudomonas aeruginosa biofilms with bacteriophages and chlorine Biotechnol Bioeng 2013; 110: 286-95.
99. Alemayehu D, Casey PG, McAuliffe O, et al. Bacteriophages. MR299-2 and MNH-4 can eliminate Pseudomonas aeruginosa in the murine lung and on cystic fibrosis lung airway cells MBio 2012; 3: e00029-12.
100. Chibeu A, Lingohr EJ, Masson L, et al. Bacteriophages with the ability to degrade uropathogenic Escherichia coli biofilms Viruses 2012; 4: 471-87.
101. Kelly D, McAuliffe O, Ross RP, Coffey A. Prevention of Staphylococcus aureus biofilm formation and reduction in established biofilm density using a combination of phage K and modified derivatives Lett Appl Microbiol 2012; 54: 286-91.
102. Liao KS, Lehman SM, Tweardy DJ, Donlan RM, Trautner BW. Bacteriophages are synergistic with bacterial interference for the prevention of Pseudomonas aeruginosa biofilm formation on urinary catheters J Appl Microbiol 2012; 113: 1530-9.
103. Montanez-Izquierdo VY, Salas-Vazquez DI, Rodriguez-Jerez JJ. Use of epifluorescence microscopy to assess the effectiveness of phage P100 in controlling Listeria monocytogenes biofilms on stainless steel surfaces Food Control 2012; 23: 470-7.
104. Ryan EM, Alkawareek MY, Donnelly RF, Gilmore BF. Synergistic phage-antibiotic combinations for the control of Escherichia coli biofilms in vitro. FEMS Immunol Med Microbiol 2012; 65: 395-8.
105. Thawal ND, Yele AB, Sahu PK, Chopade BA. Effect of a Novel Podophage AB7-IBB2 on Acinetobacter baumannii Biofilm Curr Microbiol 2012; 65: 66-72.
106. Ahiwale S, Tamboli N, Thorat K, Kulkarni R, Ackermann H, Kapadnis B. In vitro management of hospital Pseudomonas aeruginosa biofilm using indigenous T7-like lytic phage. Curr Microbiol 2011; 62: 335-40.
107. Castillo-Ruiz M, Vines ED, Montt C, et al. Isolation of a novel Aggregatibacter actinomycetemcomitans serotype b bacteriophage capable of lysing bacteria within a biofilm. Appl Environ Microbiol 2011; 77: 3157-9.
108. Cornelissen A, Ceyssens PJ, T'Syen J, et al. The T7-related Pseudomonas putida phage phi15 displays virion-associated biofilm degradation properties. PLoS One 2011; 6: e18597.
109. Knezevic P, Obreht D, Curcin S, et al. Phages of Pseudomonas aeruginosa: response to environmental factors and in vitro ability to inhibit bacterial growth and biofilm formation. J Appl Microbiol 2011; 111: 245-54.
110. Pires D, Sillankorva S, Faustino A, Azeredo J. Use of newly isolated phages for control of Pseudomonas aeruginosa PAO1 and ATCC 10145 biofilms. Res Microbiol 2011; 162: 798-806.
111. Siringan P, Connerton PL, Payne RJ, Connerton IF. Bacteriophagemediated dispersal of Campylobacter jejuni biofilms. Appl Environ Microbiol 2011; 77: 3320-6.
112. Carson L, Gorman SP, Gilmore BF. The use of lytic bacteriophages in the prevention and eradication of biofilms of Proteus mirabilis and Escherichia coli. FEMS Immunol Med Microbiol 2010; 59: 447-55.
113. Fu W, Forster T, Mayer O, Curtin JJ, Lehman SM, Donlan RM. Bacteriophage cocktail for the prevention of biofilm formation by Pseudomonas aeruginosa on catheters in an in vitro model system. Antimicrob Agents Chemother 2010; 54: 397-404.
114. Gino E, Starosvetsky J, Kurzbaum E, Armon R. Combined chemical-biological treatment for prevention/rehabilitation of clogged wells by an iron-oxidizing bacterium. Environ Sci Technol 2010; 44: 3123-9.
115. Sillankorva S, Neubauer P, Azeredo J. Phage control of dual species biofilms of Pseudomonas fluorescens and Staphylococcus lentus. Biofouling 2010; 26: 567-75.
116. Son JS, Lee SJ, Jun SY, et al. Antibacterial and biofilm removal activity of a podoviridae Staphylococcus aureus bacteriophage SAP-2 and a derived recombinant cell-wall-degrading enzyme. Appl Microbiol Biotechnol 2010; 86: 1439-49.
117. Soni KA, Nannapaneni R. Removal of Listeria monocytogenes biofilms with bacteriophage P100. J Food Prot 2010; 73: 1519-24.
118. Verma V, Harjai K, Chhibber S. Structural changes induced by a lytic bacteriophage make ciprofloxacin effective against older biofilm of Klebsiella pneumoniae. Biofouling 2010; 26: 729-37.
119. Goldman G, Starosvetsky J, Armon R. Inhibition of biofilm formation on UF membrane by use of specific bacteriophages. J Membr Sci 2009; 342: 145-52.
120. Verma V, Harjai K, Chhibber S. Restricting ciprofloxacin-induced resistant variant formation in biofilm of Klebsiella pneumoniae B5055 by complementary bacteriophage treatment. J Antimicrob Chemother 2009; 64: 1212-8.
121. Knezevic P, Petrovic O. A colorimetric microtiter plate method for assessment of phage effect on Pseudomonas aeruginosa biofilm. J Microbiol Meth 2008; 74: 114-8.
122. Sillankorva S, Oliveira R, Vieira MJ, Azeredo J. Real-time quantification of Pseudomonas fluorescens cell removal from glass surfaces due to bacteriophage fS1 application. J Appl Microbiol 2008; 105: 196-202.
123. Sillankorva S, Neubauer P, Azeredo J. Pseudomonas fluorescens biofilms subjected to phage phiIBB-PF7A. BMC Biotechnol 2008; 8: 79.
124. Cerca N, Oliveria R, Azeredo J. Susceptibility of Staphylococcus epidermidis planktonic cells and biofilms to the lytic action of staphylococcus bacteriophage K. Lett Appl Microbiol 2007; 45: 313-7.
125. Del Pozo JL, Alonso M, Arciola CR, et al. Biotechnological war against biofilms. Could phages mean the end of device-related infections? Int J Artif Organs 2007; 30: 805-12.
126. Lu TK, Collins JJ. Dispersing biofilms with engineered enzymatic bacteriophage. Proc Natl Acad Sci USA 2007; 104: 11197-202.
127. Curtin JJ, Donlan RM. Using bacteriophages to reduce formation of catheter-associated biofilms by Staphylococcus epidermidis. Antimicrob Agents Chemother 2006; 50: 1268-75.
128. Moons P, Werckx W, Van Houdt R, Aertsen A, Michiels CW. Resistance development of bacterial biofilms against bacteriophage attack. Commun Agric Appl Biol Sci 2006; 71: 297-300.
129. Sharma M, Ryu JH, Beuchat LR. Inactivation of Escherichia coli O157: H7 in biofilm on stainless steel by treatment with an alkaline cleaner and a bacteriophage. J Appl Microbiol 2005; 99: 449-59.
130. Sillankorva S, Oliveira R, Vieira MJ, Sutherland IW, Azeredo J. Bacteriophage BBS1 infection of Pseudomonas fluorescens planktonic cells versus biofilms. Biofouling 2004; 20: 133-8.
131. Corbin BD, McLean RJC, Aron GM. Bacteriophage T4 multiplication in a glucose-limited Escherichia coli biofilm. Can J Microbiol 2001 47: 680-4.
132. Hanlon GW, Denyer SP, Olliff CJ, Ibrahim LJ. Reduction in exopolysaccharide viscosity as an aid to bacteriophage penetration through Pseudomonas aeruginosa biofilms. Appl Environ Microbiol 2001; 67: 2746-53.
133. Wood HL, Holden SR, Bayston R. Susceptibility of Staphylococcus epidermidis biofilm in CSF shunts to bacteriophage attack. Eur J Ped Surgery 2001; 11: S56-S57.
134. Hughes KA, Sutherland IW, Jones MV. Biofilm susceptibility to bacteriophage attack: the role of phage-borne polysaccharide depolymerase. Microbiology 1998; 144: 3039-47.
135. Hibma AM, Jassim SA, Griffiths MW. Infection and removal of Lforms of Listeria monocytogenes with bred bacteriophage. Int J Food Microbiol 1997; 34: 197-207.
136. Doolittle MM, Cooney JJ, Caldwell DE. Tracing the interaction of bacteriophage with bacterial biofilms using fluorescent and chromogenic probes. J Indust Microbiol 1996; 16: 331-41.
137. Doolittle MM, Cooney JJ, Caldwell DE. Lytic infection of Escherichia coli biofilms by bacteriophage T4. Can J Microbiol 1995; 41: 12-8.
138. Roy B, Ackermann H-W, Pandian S, Picard G, Goulet J. Biological inactivation of adhering Listeria monocytogenes by listeriaphages and a quaternary ammonium compound. Appl Environ Microbiol 1993; 59: 2914-7.
139. Sulakvelidze A, Kutter E. Bacteriophage therapy in humans In: Kutter, E. and Sulakvelidze, A., Bacteriophages: Biology and Application. Boca Raton, Florida, CRC Press 2005; 381-436.
140. Kutter E. Phage therapy: bacteriophages as naturally occurring antimicrobials In: Goldman, E. and Green, L. H., Practical Handbook of Microbiology. Boca Raton, FL, CRC Press 2008; 713-30.
141. Chanishvili N, Malkhazova I, Khurtsia N. Phage therapy against intestinal infections In: Chanishvili, N. and Sharp, R., A Literature Review of the Practical Application of Bacteriophage Research. Tbilisi, Georgia, Eliava Institute 2009; 33-58.
142. Housby JN, Mann NH. Phage therapy. Drug Discov Today 2009; 14: 536-40.
143. Letkiewicz S, Miedzybrodzki R, Klak M, Jonczyk E, Weber-Dabrowska B, Górski A. The perspectives of the application of phage therapy in chronic bacterial prostatitis. FEMS Immunol Med Microbiol 2010 60: 99-112.
144. Miedzybrodzki R, Borysowski J, Weber-Dabrowska B, et al. Clinical aspects of phage therapy. Adv Virus Res 2012; 83: 73-121.
145. Loc-Carrillo C, Abedon ST. Pros and cons of phage therapy. Bacteriophage 2011; 1: 111-4.
146. Christie GE, Allison HA, Kuzio J, McShan M, Waldor MK, Kropinski AM. Prophage-induced changes in cellular cytochemistry and virulence In: Hyman, P. and Abedon, S. T., Bacteriophages in Health and Disease. Wallingford, UK, CABI Press 2012; 33-60.
147. Kuhl S, Hyman P, Abedon ST. Diseases caused by phages In: Hyman P. and Abedon S. T., Bacteriophages in Health and Disease. Wallingford, UK, CABI Press. 2012; 21-32.
148. Gill JJ, Hyman P. Phage choice, isolation and preparation for phage therapy. Curr Pharm Biotechnol 2010; 11: 2-14.
149. Chan BK, Abedon ST. Bacteriophage adaptation, with particular attention to issues of phage host range In: Quiberoni, A. and Reinheimer, J., Bacteriophages in Dairy Processing. Hauppauge, New York, Nova Science Publishers 2012; 25-52.
150. Chan BK, Abedon ST, Loc-Carrillo C. Phage cocktails and the future of phage therapy Future Microbiol 2013; 8: 769-83.
151. Ormala AM, Jalasvuori M. Phage therapy: Should bacterial resistance to phages be a concern, even in the long run? Bacteriophage 2013; 3: e24219.
152. Bush K, Courvalin P, Dantas G, et al. Tackling antibiotic resistance Nat Rev Microbiol 2011; 9: 894-6.
153. Hughes JM. Preserving the lifesaving power of antimicrobial agents J Am Med Assoc 2011; 305: 1027-8.
154. Lungren MP, Christensen D, Kankotia R, Falk I, Paxton BE, Kim CY. Bacteriophage K for reduction of biofilm on central venous catheter material Bacteriophage 2013; 3: e26825.
155. Singh R, Ray P, Das A, Sharma M. Penetration of antibiotics through Staphylococcus aureus and Staphylococcus epidermidis biofilms. J Antimicrob Chemother 2010; 65: 1955-8.
156. Tseng BS, Zhang W, Harrison JJ, et al. The extracellular matrix protects Pseudomonas aeruginosa biofilms by limiting the penetration of tobramycin Environ Microbiol 2013; 15: 2865-78.
157. Sertic V. Origine de la lysine d'une race du bacttriophage Compt Rend Soc Biol 1929; 100: 477.
158. Biziulevicius GA, Biziuleviciene G, Kazlauskaite J. A list of enzyme preparations covered by the term enzybiotics should not be restricted to bacteriophage-encoded peptidoglycan hydrolases (lysins). J Pharm Pharmacol 2008; 60: 531-2.
159. Skillman LC, Sutherland IW, Jones MV. The role of exopolysaccharides in dual species biofilm development. J Appl Microbiol 1999; 85: 13S-8S.
160. Mushtaq N, Redpath MB, Luzio JP, Taylor PW. Prevention and cure of systemic Escherichia coli K1 infection by modification of the bacterial phenotype. Antimicrob Agents Chemother 2004; 48: 1503-8.
161. Mushtaq N, Redpath MB, Luzio JP, Taylor PW. Treatment of experimental Escherichia coli infection with recombinant bacteriophage-derived capsule depolymerase. J Antimicrob Chemother 2005; 56: 160-5.
162. Scorpio A, Tobery SA, Ribot WJ, Friedlander AM. Treatment of experimental anthrax with recombinant capsule depolymerase. Antimicrob Agents Chemother 2008; 52: 1014-20.
163. Scorpio A, Chabot DJ, Day WA, et al. Poly-.-glutamate capsuledegrading enzyme treatment enhances phagocytosis and killing of encapsulated Bacillus anthracis. Antimicrob Agents Chemother 2007; 51: 215-22.
164. Avery OT, Dubos R. The protective action of a specific enzyme against type III pneumococcus infection in mice. J Exp Med 1931; 54: 73-89.
165. Goodner KR, Dubos R, Avery OT. The action of a specific enzyme upon the dermal infection of rabbits with type III pneumococcus. J Exp Med 1932; 55: 393-404.
166. Waseh S, Hanifi-Moghaddam P, Coleman R, et al. Orally administered P22 phage tailspike protein reduces salmonella colonization in chickens: prospects of a novel therapy against bacterial infections PLoS One 2010; 5: e13904.
167. Prevelige PE Jr. Bacteriophage P22 In: Calendar, R. and Abedon, S. T., The Bacteriophages. Oxford, Oxford University Press 2006; 457-68.
168. Steinbacher S, Miller S, Baxa U, et al. Phage P22 tailspike protein: crystal structure of the head-binding domain at 2. 3 A, fully refined structure of the endorhamnosidase at 1. 56 A resolution, and the molecular basis of O-antigen recognition and cleavage. J Mol Biol 1997; 267: 865-80.
169. Bull JJ, Vimr ER, Molineux IJ. A tale of tails: Sialidase is key to success in a model of phage therapy against K1-capsulated Escherichia coli. Virology 2010; 398: 79-86.
170. Bull JJ, Otto G, Molineux IJ. In vivo growth rates are poorly correlated with phage therapy success in a mouse infection model. Antimicrob Agents Chemother 2012; 56: 949-54.
171. Smith HW, Huggins MB. Successful treatment of experimental Escherichia coli infections in mice using phage: Its general superiority over antibiotics. J Gen Microbiol 1982; 128: 307-18.
172. Levin BR, Bull JJ. Phage therapy revisited: the population biology of a bacterial infection and its treatment with bacteriophage and antibiotics. Am Nat 1996; 147: 881-98.
173. Lindberg AA. Bacterial surface carbohydrates and bacteriophage adsorption In: Sutherland, I. W., Surface Carbohydrates of the Prokaryotic Cell. London, Academic Press 1977; 289-356.
174. Weinbauer MG. Ecology of prokaryotic viruses. FEMS Microbiol Rev 2004; 28: 127-81.
175. Scholl D, Adhya S, Merril C. Escherichia coli K1's capsule is a barrier to bacteriophage T7. Appl Environ Microbiol 2005; 71: 4872-4.
176. Itoh Y, Wang X, Hinnebusch BJ, Preston JF, III Romeo T. Depolymerization of D-1, 6-N-acetyl-D-glucosamine disrupts the integrity of diverse bacterial biofilms. J Bacteriol 2005; 187: 382-7.
177. Gladstone EG, Molineux IJ, Bull JJ. Evolutionary principles and synthetic biology: avoiding a molecular tragedy of the commons with an engineered phage. J Biol Eng 2012; 6: 13.
178. Young R, Wang I-N. Phage lysis In: Calendar R, Abedon ST. The Bacteriophages. Oxford, Oxford University Press 2006; 104-25.
179. Loeffler JM, Nelson D, Fischetti VA. Rapid killing of Streptococcus pneumoniae with a bacteriophage cell wall hydrolase. Science 2001; 294: 2170-2.
180. Schuch R, Nelson D, Fischetti VA. A bacteriolytic agent that detects and kills Bacillus anthracis. Nature 2002; 418: 884-9.
181. Walmagh M, Boczkowska B, Grymonprez B, Briers Y, Drulis-Kawa Z, Lavigne R. Characterization of five novel endolysins from Gram-negative infecting bacteriophages Appl Microbiol Biotechnol 2013; 97: 4369-75.
182. Fenton M, Keary R, McAuliffe O, Ross RP, O'Mahony J, Coffey A. Bacteriophage-derived peptidase CHAP(K) eliminates and prevents staphylococcal biofilms. Int J Microbiol 2013; 2013: 625341.
183. Jun SY, Jung GM, Yoon SJ, et al. Antibacterial properties of a preformulated recombinant phage endolysin, SAL-1. Int J Antimicrob Agents 2013; 41: 156-61.
184. Shen Y, Koller T, Kreikemeyer B, Nelson DC. Rapid degradation of Streptococcus pyogenes biofilms by PlyC, a bacteriophageencoded endolysin. J Antimicrob Chemother 2013; 68: 1818-24.
185. Meng X, Shi Y, Ji W, et al. Application of a bacteriophage lysin to disrupt biofilms formed by the animal pathogen Streptococcus suis. Appl Environ Microbiol 2011; 77: 8272-9.
186. Sass P, Bierbaum G. Lytic activity of recombinant bacteriophage phi11 and phi12 endolysins on whole cells and biofilms of Staphylococcus aureus. Appl Environ Microbiol 2007; 73: 347-52.
187. Melly MA, Duke LJ, Liau DF, Hash JH. Biological properties of the encapsulated Staphylococcus aureus M. Infect Immun 1974; 10: 389-97.
188. Peterson PK, Wilkinson BJ, Kim Y, Schmeling D, Quie PG. Influence of encapsulation on staphylococcal opsonization and phagocytosis by human polymorphonuclear leukocytes Infect Immun 1978; 19: 943-9.
189. Domenech M, Garcia E, Moscoso M. In vitro destruction of Streptococcus pneumoniae biofilms with bacterial and phage peptidoglycan hydrolases. Antimicrob Agents Chemother 2011; 55: 4144-8.